Two Speculative Biotech Buys
There seems to be some strong M&A activity going on in the biotech and drug sectors recently. On Monday, GlaxoSmithKline (GSK) finally won in its fight to take over Human Genome Sciences (HGSI) for twice what the stock was trading at late last year.
In addition, the drug sector looks ripe for some increased activity from hedge funds and private-equity firms that see value in the space. This was demonstrated by yesterday's announcement that the private-equity firm TPG Capital acquired Par Pharmaceuticals (PRX) for an almost 40% premium....330 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.